Difficulties Diagnosing Progressive Multifocal Leukoencephalopathy in Patients Infected with the Human Immunodeficiency Virus – Case Reports

Česká verze

Authors: H. Rozsypal ¹; D. Jilich ¹; P. Hubáček ²; M. Holub ¹
Authors place of work: Klinika infekčních a tropických nemocí 1. LF UK a Nemocnice Na Bulovce, Praha ¹; Laboratoř molekulární genetiky, Ústav lékařské mikrobiologie a Klinika dětské hematologie a onkologie 2. LF UK a FN v Motole, Praha ²
Published in the journal: Cesk Slov Neurol N 2013; 76/109(4): 501-507
Category: Kazuistika

Práce vznikla s podporou výzkumného záměru PRVOUK P2/ 1LF/ 3, podpořeno projektem MZČR koncepčního rozvoje FN Motol 00064203 a v rámci specifického vysokoškolského výzkumu SVV‑ 2012- 264506.

Autoři děkují MU Dr. Miroslavu Kašparovi, CSc., za poskytnutí CT a MR snímků.

Summary

Progressive Multifocal Leukoencephalopathy (PML) is a focal inflammatory process of white brain matter induced by polyomaviral infection that affects HIV‑ positive individuals, patients with hematologic malignancies and recently also patients on a biological treatment. PML is a typical opportunistic infection of patients with AIDS. Examination with magnetic resonance imaging (MRI) and detection of JC virus (JCV) DNA in the cerebrospinal fluid (CSF) are the most important approaches to the diagnosis of PML. Case reports document that PML diagnosis is not easy. The disease may develop before the number of CD4+ lymphocytes drops below 100 cells/ µl. Appearance of lesions on a CT scan and MRI is not completely specific and may be mistaken for brain toxoplasmosis, an ischemic lesion or other intracranial processes; sometimes it can start with one lesion only, suggesting a unifocal process. The paper draws a reader’s attention to the use of molecular biological diagnostics. It describes initial experience with JCV detection in the CSF using PCR in the Czech Republic and, at the same time, it discusses limited sensitivity of the method. PML prognosis is poor but disease progression can be slowed down by well managed combined antiretroviral therapy (cART). The initiation of cART in persons with severe immunodeficiency may in rare cases lead to paradoxical development of PML as a sign of immune reconstitution inflammatory syndrome (IRIS).

Key words:
progressive multifocal leukoencephalopathy – human immunodeficiency virus – acquired immunodeficiency syndrome – JC virus

Zdroje

1. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354(9): 924– 933.

2. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV‑ negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project. Blood 2009; 113(20): 4834– 4840.

3. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus‑induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5(1): 49– 73.

4. Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9(4): 425– 437.

5. Eng PM, Turnbull BR, Cook SF, Davidson JE, Kurth T, Seeger JD. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 2006; 67(5): 884– 886.

6. Antinori A, Ammassari A, Giancola ML, Cingolani A,Grisetti S, Murri R et al. Epidemiology and prognosis of AIDS‑associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001; 7(4): 323– 328.

7. Naess H, Glad S, Storstein A, Rinaldo CH, Mørk SJ, Myhr KM et al. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurology 2010; 10: 32.

8. Vaklavas C, Sotelo‑ Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J 2010; 7: 256.

9. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127(4): 467– 470.

10. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P,Brown DW et al. Population‑based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71(1): 115– 123.

11. Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997; 176(1): 250– 254.

12. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy – revisited. J Infect Dis 2011; 203(5): 578– 586.

13. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome‑associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44(3): 341– 349.

14. Smith AB, Smirniotopoulos JG. Imaging evaluation of demyelinating processes of the central nervous system. Postgrad Med J 2010; 86(1014): 218– 229.

15. Černý R, Kapla J, Machala L. Ložiskové léze CNS u pacientů s HIV infekcí. Cesk Slov Neurol N 2010; 73/ 106(4): 374– 378.

16. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia‑ Etxaburu J et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36(8): 1047– 1052.

17. Falcó V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M et al. Influence of HAART on the clinical course of HIV‑ 1– infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 2008; 49(1): 26– 31.

18. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73(19): 1551– 1558.

19. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338(19): 1345– 1351.

20. Vollmer‑ Haase J, Young P, Ringelstein EB. Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet 1997; 349: 1366.

21. Royal W 3rd, Dupont B, McGuire D, Chang L, Goodkin K, Ernst T et al. Topotecan in the treatment of acquired immunodeficiency syndrome‑related progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9(3): 411– 419.

22. O’Reilly S. Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet 1997; 350(9073): 291.

23. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS‑associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22(14): 1759– 1767.

24. Wyen C, Hoffmann C, Schmeisser N, Wöhrmann A,Qurishi N, Rockstroh J et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37(2): 1263– 1268.

25. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S,Manley K et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306(5700): 1380– 1383.

26. Verma S, Cikurel K, Koralnik IJ, Morgello S, Cunningham‑ Rundles C, Weinstein ZR et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196(5): 709– 711.

27. Focosi D, Kast RE, Maggi F, Ceccherini‑Nelli L, Petrini M. Risperidone‑induced reduction in JC viruria as a surrogate marker for efficacy against progressive multifocal leukoencephalopathy and hemorrhagic cystitis. J Clin Virol 2007; 39(1): 63– 64.

28. Focosi D, Kast RE, Maggi F, Lauria G, Ceccherini‑Nelli L, Petrini M. 5- HT2a inhibitors for progressive multifocal leukoencephalopathy: old drugs for an old disease. J Infect Dis 2008; 197(2): 328.

29. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus‑ infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66(2): 255– 258.

30. Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving HAART. Clin Infect Dis 1999; 28(5): 1152– 1154.

31. Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Mertenskötter T et al. HAART significantly improves the prognosis of patients with HIV‑associated progressive multifocal leukoencephalopathy. AIDS 1998; 12(10): 1149– 1154.

32. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ et al. HAART improves prognosis in HIV‑associated progressive multifocal leukoencephalopathy. Neurology 1999; 52(3): 623– 625.

33. Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of HIV‑ infected patients in the protease inhibitor era. J Infect Dis 1999; 180(3): 621– 625.

34. Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA et al. JC virus‑ specific immune responses in HIV‑ 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009; 83(9): 4404– 4011.

35. Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M,Fux CA et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48(10): 459– 466.

36. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV‑ infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199(1): 77– 83.

37. Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003; 74(8): 1142– 1144.

38. Marzocchetti A, Sanguinetti M, Giambenedetto SD, Cingolani A, Fadda G, Cauda R et al. Characterization of JC virus in cerebrospinal fluid from HIV‑ 1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. J Neurovirol 2007; 13(4): 338– 346.

39. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73(19): 1551– 1558.

40. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML‑IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72(17): 1458– 1464.

41. EACS (European AIDS Clinical Society) Guidelines. Version 6.0 – October 2011 [online]. Available from: http:/ / www.europeanaidsclinicalsociety.org/ .

42. Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M,Fux CA et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48(10): 1459– 1466.

43. Nery F, Franca M, Almeida I, Vasconcelos C. From clinical presentation to the outcome: the natural history of PML in a Portuguese population of HIV infected patients. J Clin Med Res 2011; 3(1): 17– 22.

44. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV‑ infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199(1): 77– 83.

45. SZÚ. Údaje Národní referenční laboratoře pro AIDS [online]. Available from: http:/ / www.szu.cz/ uploads/ documents/ CeM/ HIV_AIDS/ rocni_zpravy/ 2012/ HIV_AIDS_08_2012.pdf.

46. Eggers C, Stellbrink HJ, Buhk T, Dörries K. Quantification of JC virus DNA in the cerebrospinal fluid of patients with HIV‑associated PML – a longitudinal study. J Infect Dis 1999; 180(5): 1690– 1694.

47. García De Viedma D, Díaz Infantes M, Miralles P, Berenguer J, Marín M, Muñoz L et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis 2002; 34(12): 1568– 1575.

48. Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV‑associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005; 40(5): 738– 744.

49. Delobel P, Brassat D, Delisle MB, Scaravilli F, Clanet M. Progressive multifocal leukoencephalopathy in an HIV patient with normal CD4 T‑ cell count and magnetic resonance imaging. AIDS 2004; 18(4): 702– 704.

50. Wang Y, Kirby JE, Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol 2009; 58(Pt 2): 253– 255.